Introduction {#S1}
============

For longer than four decades, there has been an ongoing debate about the role of brain dopamine (DA) in reward and addiction. Nutt, Lingford-Hughes, Erritzoe, and Stokes ([@B58]) proposed that DA may be central to psychostimulant dependence and possibly for alcohol dependence but not requisite for opiates, nicotine, or even cannabis dependence ([@B58]). This view may be overly simplistic, as our group has noted in earlier publications, distinction between what constitutes "surfeit," compared with "deficit," regarding short-term (acute) and long-term (chronic) brain reward circuitry responsivity ([@B20]). Others have also argued that surfeit theories of DA can explain, e.g., cocaine-seeking behavior as well as responses concerning dominant rats with elevated DA compared with subordinate rats ([@B44]).

In an earlier study, we attempted to resolve controversy, concerning the contribution of mesolimbic DA systems to reward, by invoking three, competing, explanatory categories, namely, "liking," "learning," and "wanting" ([@B20]). Specifically, they are (a) the hedonic impact -- "liking" reward, (b) the ability to predict rewarding effects "learning," and (c) the incentive/salience of reward-related stimuli "wanting."

Concerning acute effects, most of the evidence favors the "surfeit theory." We know that because of preferential DA release in the mesolimbic--ventral tegmental area (VTA)--caudate--accumbens loci, many drugs of abuse and reward deficiency syndrome (RDS). These behaviors have been linked to heightened feelings of well-being and hyperdopaminergic states ([@B6]; [@B7]).

The "dopamine hypotheses" is now believed to be quite complicated, encoding the set point of hedonic tone, attention, reward expectancy, and incentive motivation ([@B62]; [@B72]). Willhuhn et al. ([@B72]) have shown in a self-administration paradigm (chronic), excessive use of cocaine is associated with decreased, phasic DA signaling in the striatum. Others have shown blunted reward sites responsivity with chronic addictions, e.g., food ([@B63]), nicotine ([@B42]), and gambling behavior ([@B40]; [@B60]).

The contention is that the differences in dopaminergic function, which occur, as addictions progress can be impacted by both genetics and negative and positive environmental factors, such as epigenetics ([@B41]). One significant effect of dopaminergic deficiency may be linked to relapse and behavioral reinstatement ([@B33]). In particular, addictive-like behaviors (e.g., hoarding and shopping) can result from the cumulative effects of dopaminergic and other neurotransmitter genetic variants as well as elevated stress levels. Thus, DA homeostasis may be the preferred goal in combating such challenging and unwanted behaviors, when simple dopaminergic activation through potent agonists may not provide any resolution.

DA and Motivation {#S2}
=================

DA neurons in the midbrain play a role in motivation as well as in the regulation of mood and the induction of reward-aversion ([@B43]; [@B48]; [@B65]). While much of this evidence points to the loci of this effect of DA being the ventral tegmental area (VTA), other evidence suggests that the motivational and other effects of DA on behavior may also derive from the substantia nigra ([@B43]; [@B47]).

It has been shown that, while high extracellular concentrations of DA induce euphoria, low levels of DA induce "seeking" and aversive behavioral states. For example, Ng et al. ([@B57]) have demonstrated that neuronal calcium sensor-1, a substrate that regulates neuronal D2 expression and subsequent release at the nucleus accumbens (NAc), when deleted in the mouse's brain, causes a reduced release of DA and subsequently decreased motivation. Other very recent work by Korte et al. ([@B46]) evaluated the role of the 5-HT1A/1B-receptor activation and showed that the 5-HT1A/1B-receptor agonist, eltoprazine, increases both DA release in the NAc and catecholamine release in the prefrontal cortex. This agonist also decreases motivation for reward and "waiting" impulsivity but increases "stopping" impulsivity.

In addition, the D1 DA receptor-mediated, long-term potentiation, at gamma-aminobutyric acid (GABA) synapses encodes motivation to self-administer cocaine in rats ([@B47]). We hypothesize that the enhanced signal to increase cocaine self-administration agrees with the report of Willuhn, Burgeno, Everitt, and Phillips ([@B71]), which demonstrated that as DA levels go down, as cocaine use increases. This enhancement was further supported by the work of others ([@B9]; [@B36]).

The behavior of the woman, in this case study diagnosed with attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD), is consistent with the findings of Volkow's group regarding DA reward pathway dysfunction. They correlated positron emission tomography (PET) measures of DA D2/D3 receptor, as well as, DA transporter availability (measured using \[(11)C\]raclopride and \[(11)C\]cocaine, respectively) within the DA reward pathways. The DA pathways included the midbrain and NAc, with a measure of trait motivation (the achievement scale from the Multidimensional Personality Questionnaire). These authors suggested that disruption of the DA reward pathway is associated with motivation deficits in ADHD adults, which may contribute to the observed attention deficits. This finding suggests that pro-dopamine regulation, as a way of inducing "dopamine homeostasis," may constitute a means of normalizing motivation in ADHD as well as SUD ([@B68]).

DA and Excessive Hoarding and Shopping Behaviors {#S3}
================================================

While generally, it is agreed that dopaminergic function influences motivation and that certain deficits in the brain reward pathway can impact impulsivity (hoarding and shopping excesses), a piece of the treatment puzzle may be missing.

A review of the literature (PUBMED 5/14/17) reveals that there are many studies involving food-hoarding behavior ([@B56]; [@B73]), but a paucity of information on the role of DA in non-food hoarding behavior. In fact, some reports are suggesting that hoarding behavior is associated with a *hyperdopaminergic* trait/state and subsequent blocking of D2 receptors seems to improve the condition ([@B27]). Earlier work by Kelley and Stinus ([@B45]) showed that while 6-hydroxydopamine lesions of the mesolimbic DA neurons eliminated hoarding behavior in rats, L-Dopa administration was associated with a reinstatement of this behavior. Other genetic work seems to support these earlier studies, with female hoarders. These people tend to exhibit a greater frequency of the low activity Met/Met genotype of Val158Met polymorphism, compared with females, who did not express this change, suggesting a higher concentration of DA in the synapse ([@B53]).

Fontenelle, Oostermeijer, Harrison, Pantelis, and Yucel ([@B39]) also suggested that obsessive--compulsive disorder, impulse control disorders, and drug addiction have common, dopaminergic features and that therapeutic intervention of these disorders should involve DA as a target. Regarding excessive shopping behavior and dopaminergic function, much less is known, except for reports regarding these behaviors and Parkinson Disease ([@B30]; [@B59]; [@B69]). We contend that whether there is a hyper or hypodopaminergia, balancing the dopaminergic trait/state, especially, with a well-researched, pro-dopamine regulator, KB220, should show benefit the treatment of both excessive hoarding and shopping in a middle-aged female, diagnosed with both ADHD and SUD.

KB220 {#S4}
=====

The most recent variant of KB220Z (powdered form) used in this study is composed of the following ingredients: 10 mg (500%) vitamin B6, 15 mg (1,033% of daily value) thiamine, 200 mcg (166%) chromium poly nictitate, and a fixed dose of synaptose. Synaptose is a combination of amino acids and herbs. The amino acids include L-tyrosine, DL-phenylalanine, L-glutamine, and 5-hydroxytryptophan. The herbs include passionflower extract and a complex containing astragalus, arabinogalactans, N-acetylglucosamine, aloe vera, white pine bark extract, frankincense resin Spirulina Rhodiola, as well as, thiamine hydrochloride, pyroxidal-5-phosphate, pyridoxine HCl, and N-acetylglucosamine, an amino sugar. The powder was manufactured by Cephram, Inc. (New Jersey). One other version used was the liquid nano form of the same ingredients.

Characteristics and neuropharmacology of KB220 variants {#S4a}
-------------------------------------------------------

It is noteworthy that over 40 years of research over many variants and 36 published articles, many clinical benefits have been observed from double-blind placebo-controlled trials, randomized placebo-control studies, case reports, and neuroimaging studies in both humans and animals.

The following information should provide evidence for clinical benefit of evaluating KB220Z in this study, begging the question of neuromechanisms involved in producing DA homeostasis. Variations of KB220 nutraceutical complex have been studied extensively in preclinical and human trials. As reported in a detailed review article ([@B16]), to date, KB220 variants have demonstrated the ability to enhance brain enkephalin levels in in C57/BL mice, thereby reducing alcohol-seeking behavior and pharmacogenetically convert acceptance in DBA ethanol preferring mice to non-preference as in 2J mice ([@B12]). In humans, KB220 has reduced alcohol and drug and withdrawal symptomatology ([@B21]; [@B26]). Specifically, lowering the need for benzodiazepines, reducing the days with withdrawal tremors, no severe depression on the Minnesota Multiphasic Personality Inventory, and a lower score building up to drink score ([@B25]). In recovery patients, demonstrated a reduced stress response, measured by the level of skin conductance, and significantly improved physical and behavioral, emotional, social and spiritual scores ([@B25]). After detoxification, the KB220 variant group demonstrated a sixfold decrease in leaving against medical advice (AMA) rates in comparison with the placebo group ([@B10]; [@B25]) and KB220 enhanced the focus of healthy volunteers ([@B35]). There is also evidence that KB220 reduced craving for alcohol ([@B28]), heroin, cocaine ([@B31]), food ([@B8]), inappropriate sexual behavior ([@B52]), and post-traumatic stress symptomatology, such as lucid nightmares ([@B49]). Quantitative Electroencephalogram (qEEG) studies in humans have found that KB220Z modulates theta power in anterior cingulate cortex ([@B13]). Compared with placebo, a single dose of KB220Z in a pilot study of abstinent heroin addicts resulted in NAc activation and improvement in activation of the prefrontal--cerebellar--occipital neural network ([@B23]). Known obese carriers of the DRD2 A1 allele showed enhanced compliance with KB220Z treatment, demonstrating weight loss and a significant Pearson's correlation, relative to carriers of the DRD2 A2 allele with a usual complement DRD2 receptors ([@B100]). This result suggests the importance of balanced DA function equates to better treatment outcome.

To assist in understanding the intensive research on KB220 variants, we encourage scrutiny of some reviews on the subject ([@B15]; [@B16]). These studies, including double-blinded control studies and qEEG, have demonstrated positive effects on both craving attenuation and relapse prevention and reduction in AMA rates; see review ([@B21]).

Are KB220 variants putative modulators of DA homeostasis? {#S4b}
---------------------------------------------------------

The development of KB220Z followed the first report concerning the enkephalinase inhibitor D-phenylalanine ([@B25]). The unique design of the KB220Z complex follows the brain reward cascade with the ultimate intent of facilitating DA release throughout the reward circuitry. While, as yet, the actual release of DA has not been determined we plan to study DA release using a single scan dynamic molecular imaging technique to understand the nature of DA released in the human and animal brains following administration of KB220Z ([@B4]). This specific technique allows detection, mapping, and measurement of DA released endogenously following a pharmacological or behavioral challenge ([@B3]; [@B5]). This molecular imaging technique was used to observe DA release in some of the same areas where enhanced connectivity was seen in the current experiment ([@B2]).

The hypothesis here is that these robust and selective results are due to inhibition of GABA transmission within the substantia nigra via serotonergic--opioidergic--glutaminergic interactions that reduce the inhibitory control of GABA over DA release throughout the reward network ([@B67]). In support of these findings, similar results were found in humans showing enhanced regulation of deregulated widespread theta in the cingulate gyrus of abstinent psychostimulant abusers. Alpha and low beta waves were increased 1 hr after KB220Z administration ([@B13]). Previously, our laboratory found resting state functional abnormalities in abstinent heroin-dependent individuals affecting functional brain organization, which could negatively impact decision-making and inhibitory control ([@B55]). Moreover, compared with healthy controls, heroin addicts showed reduced activation in right amygdala in response to the affective pictures ([@B23]), consistent with previous reports of blunted subjective experience for affective stimuli in obese carriers of the DRD2 a1 allele ([@B63]). Brain scans of these abstinent heroin addicts show evidence for "dopamine homeostasis" following 1 hr KB220Z administration: BOLD activation of caudate with reduced activation in putamen ([@B23]). Other studies showed persistent abnormalities in the brain function following 1 month of heroin withdrawal in the orbitofrontal cortex ([@B74]). Zijlstra et al. also found lower baseline D2R availability in opiate-dependent subjects than in the left caudate nucleus of controls. After cue-exposure, opiate-dependent subjects demonstrated higher DA release in the right putamen than controls; this release positively correlated with chronic craving and anhedonia. DA 2R availability in the putamen was negatively correlated with years of opiate use ([@B75]). Treatment strategies that increase D2Rs may be an approach that could prevent relapse not only in opiate addiction but also other behavioral addictions, such as hoarding and excessive shopping ([@B34]). There is extensive evidence that indicates that current and recently abstinent cocaine abusers compared with drug-naive controls have decreased gray matter in regions, such as the anterior cingulate, lateral prefrontal, and insular cortex ([@B67]). Following optogenetic stimulation of the rat NAc, brain regions crucial for cognitive processing including the dorsal hippocampus, anterior thalamus, and regions the central striatal reward structure were also observed to have changes in metabolic activity. Small animal PET and \[18F\]2-fluoro-2-deoxy-D-glucose ([@B64]) or presentation of cues ([@B54]) were used to observe these changes. Wang et al. have shown a dysfunction of the frontostriatal and frontocerebellar circuits in heroin addicts. The altered function implies an altered balance between local neuronal assembly's activities and their integrated network organizational pattern that may be involved in the process of moving from voluntary to habitual and compulsive drug use and possibly behavioral compulsion ([@B70]). In a human pilot study, KB220Z demonstrated improvement in the cerebellum, the cingulated, and other areas of the reward circuitry in abstinent heroin addicts ([@B23]).

Importantly, the finding reported by Connolly, Bell, Foxe, and Garavan ([@B32]), of increased areas of activation could have therapeutic value, especially considering the reduced brain gray matter volume during cocaine administration to humans. It is plausible that KB220Z due to COMT inhibition (via Rhodiola Rosea) could result in larger amounts of DA in the synapse, and for that reason enhanced DA activity ([@B10]).

One element of the reward circuitry, the mesolimbic DA system in the brain, controls human responses to food, social interactions, and money, and is, therefore, an influential determinant of rewards and motivation. The midbrain DA neurons that project to the striatum are involved in producing the reward. In an animal study, Febo et al. ([@B37]) illustrated the modulatory actions of a putative DA agonist (KB220Z) on the rsFC in association with a key region of the reward system, the NAc. The finding is that KB220Z, like optogenetic stimulation of the rat NAc ([@B64]), caused an increase in the connectivity between this central striatal reward structure and the dorsal hippocampus and anterior thalamus, areas crucial for cognition. Indeed, recent work from Ferenczi et al. demonstrated that midbrain DA neuron stimulation drives both reward-seeking behavior and striatal fMRI BOLD activity. They also showed that silencing of DA neurons drives avoidance behavior ([@B11]; [@B38]) and suppresses response in the striatum, as well as other brain regions like the hypothalamus. In addition, suppression of striatal responses to DA and inhibition of the behavioral drive to seek out natural rewarding stimuli through DA neuron stimulation were observed following DA neuron silencing. Most importantly, Ferenczi et al., demonstrated that medial prefrontal cortex (mPFC) excitability that is consistently elevated, synchronizes corticolimbic BOLD, and electrophysiological activity, which can, in turn, predict anhedonic behavior in individual animals ([@B22]; [@B38]). Interestingly, mPFC has glutaminergic neuronal input, and as such, there is a need to balance and optimize the fine interaction between mPFC--glutaminergic input to striatal midbrain DA, so that the resultant release of DA at the VTA--NAc is balanced ([@B15]; [@B16]). These new findings have direct implications for the notable observation that KB220Z potentially may induce BOLD activation due to a glutaminergic--dopaminergic optimization.

Case Report {#S5}
===========

Identifying information {#S5a}
-----------------------

C.J. is a 38-year-old, unmarried, female, and living with her mother. She is currently treated for ADHD, inattentive type, and SUD. Her ADHD diagnosis was based on her performance on the Connors' Continuous Performance Test II (CPT II V.5) and her clinical history. Her SUD diagnosis was based upon her history and psychiatric evaluations over a 7-year period.

Ethics {#S5b}
------

The patient signed a consent form and the case study is part of an approved IRB from Path Foundation NY.

Past psychiatric history {#S5c}
------------------------

### Hospitalizations {#S5c1}

1.  A psychiatric hospitalization at 16 years of age for a "marijuana addiction;"

2.  A psychiatric hospitalization at 15 years of age, when patient was diagnosed with "bipolar disorder;"

3.  A 6-month, psychiatric hospitalization, at the age of 14 for oppositional defiant disorder and intermittent explosive disorder signs and symptoms.

### Psychotherapy {#S5c2}

Patient engaged in individual psychotherapy regularly from 25 years of age to the present.

Abuse history {#S5d}
-------------

The patient reports a history of verbal/emotional abuse by her mother, who frequently called her a "bitch," and a "whore." She claims physical abuse by her mother from 3 to 6 years of age.

Family psychiatric history {#S5e}
--------------------------

The patient maintains her mother had "untreated bipolar disorder" (although the mother's frequent use of coprolalia raises the question about "vocal tics" and, possibly, Tourette's syndrome).

Family history {#S5f}
--------------

The patient's mother is rageful, abusive, and hypercritical. She was unaffectionate and, otherwise, inattentive to the patient throughout her childhood.

The patient's father is deceased. She mourned his death. He is remembered as having been "kind, attentive, and affectionate."

Family addiction history {#S5g}
------------------------

The patient's father was addicted to alcohol and heroin. Her mother is addicted to food, cigarettes, and hoarding. The patient's brother was addicted to opiates and is currently treated with methadone. The patient's sister was addicted to heroin and is currently treated with methadone.

ADHD history {#S5h}
------------

The patient states, during grade school, she was spacey, dreamy, easily distracted, and bored.

### Motor tics {#S5h1}

The patient cracks her fingers frequently. She also twists her torso, grinds her teeth, and picks her skin.

### Vocal tics {#S5h2}

The patient reports that, on a daily basis, she hums, talks to herself, clears her throat, and engages in both habitual coprolalia and palilalia.

Social history {#S5i}
--------------

The patient has a General Equivalency Diploma, with some community college courses. She was never married and had no children. She has had two abortions, one involving twins. She lived in foster homes from age 13 to 17, because "my mom was out of control."

Past medical history {#S5j}
--------------------

The patient denies any history of hypertension, heart disease, asthma, or any history of head injury.

### Allergies {#S5j1}

The patient denies any history of allergies to food or medication.

### Dreamlife {#S5j2}

The patient notes an onset of lucid dreams at about 5 years of age. These dreams, which were characterized as seeming "like... (she)... was "fully awake," occurred nightly into adulthood. Their content was unpleasant or terrifying "100% of the time." The themes of the dreams usually involved fears of being chased, stabbed, or murdered. These scary dreams led her to feel "paranoid" in the daytime as well. She reports awareness, during these lucid dreams that she is, in fact, dreaming. She reports an ability to control the onset or offset of these lucid dreams.

The patient was given the nutraceutical, KB220Z at four tablets a day, for 6 months, to influence her dreamlife, because of the experience by one of the authors that its use ameliorated such dreams. After following this regimen for 6 months, she reported her lucid dreams gradually remitted. She also noted increased "mental energy;" during this time, she took the KB220Z. Later, she reported that she no longer had lucid dreams, despite having stopped the KB220Z 2 years prior ([@B49]; [@B50]; [@B51]).

Patient's addiction history {#S5k}
---------------------------

The patient reported a remote history of marijuana addiction, at 16 years of age. She also admitted to an opiate addiction for 10 years as well as a history of both shopping and hoarding addictions for this same period. The patient smokes an average of one pack of cigarettes a day and drinks 20 cups of coffee a day.

### Medication regimen {#S5k1}

Buprenorphine/naloxone combination treatment history at her current clinic.

For 5 years, the patient has been maintained on buprenorphine/naloxone combination of 8 mg/2 mg, one tablet sublingual twice a day. In addition to counseling, she attends monthly visits for her buprenorphine/naloxone combination prescriptions. During the period, since she was first seen at the clinic, she has denied any relapses, cravings, or drug use. She has been able to decrease her dose to 1½ buprenorphine/naloxone combination of 8 mg/2 mg sublingual a day.

From January 2016 to the present, the patient has also been maintained on mixed amphetamine salts \[NIH National Library of Medicine\] IR 30 mg every morning and 20 mg every afternoon. In addition, she is maintained on gabapentin 300 mg TID. The KB220Z compound was an addition to these medications.

### Random toxicology screens {#S5k2}

The patient has had clean, random, toxicology screens; during the 5 years, she has been treated at the clinic.

Work stressors {#S5l}
--------------

The patient states that she has suffered from job stress for the past 3 ½ years. This stress resulted from what she perceives to be discrimination by supervisors as well as her need to work the night shift and not getting enough sleep during the day.

Recent stressors {#S5m}
----------------

Three months prior, the patient reported frequent rage while driving. She stated some of this emotion had to do with her being late for work (tardiness has been an ongoing problem). During this same period, she complained of increased apathy but denied cravings, relapse, or use of substances. She continued to report stress at work.

Eventually, she lost her job, because she had overslept and failed to call into work. She was denied unemployment benefits and became severely "depressed" and unmotivated. She was given the "liquid-nano" KB200z, to augment the dopaminergic treatment (dextroamphetamine/amphetamine mixture) of her presumed, RDS ([@B24]).

Phenomenological/psychological report of the effects of KB200z in a patient evidencing RDS {#S5n}
------------------------------------------------------------------------------------------

At this point, the patient showed cell phone pictures of her overly cluttered and hoarding-filled room, which represented its state, before taking KB200Z. After taking her KB220Z, each morning for 1 month, she had completely decluttered her apartment as seen in her post-liquid nano KB220Z photo (Figure [1](#fig1){ref-type="fig"}) and the change in hours per week spent shopping (Figure [2](#fig2){ref-type="fig"}).

![Patient's home *before* use of KB220Z (left: A) and *after* 30 days on KB220Z (right: B). This patient admitted to a history of ADHD, opiate addiction, shopping addiction, and hoarding addiction. Traditionally, such diagnoses and behavioral addictions have been treated with pharmacotherapy (ADHD) and, more recently, with nutraceutical formulas, such as KB200z. There are, to date, no reports of the alleviation of shopping and hoarding addictions with any known pharmaceutical to our knowledge](jba-07-01-081_f001){#fig1}

![Hours per week shopping before KB220Z and after 30 days of KB220Z. The above figure depicts the change in hours spent per week shopping (42 hr/week for 2--3 years) to 0 hr/week after taking KB200z for 1 month. The change has, in fact, persisted for 2 weeks beyond the active ingestion period of 1 month on a daily basis at 1 oz a day (patient has recently reordered a new supply)](jba-07-01-081_f002){#fig2}

Even though there are, to date, 30 studies demonstrating the therapeutic and anti-addictive effects, there are none which demonstrate an anti-shopping or an anti-hoarding effect ([@B37]). Moreover, this is the first report to ([@B1]) describe the psychological effect of the patient's ingestion of KB200z. These effects include her improved self-esteem, her change from a "passive victim" to a more active agent in control of her own life -- in short, a change in her experience of herself and her identity. The following are the patient's own words, presented in their unedited form:""The month of March 2017 is when I began to drink the liquid nano KB220Z, and it worked fairly quickly for me. In fact I feel like it was almost immediate. However, realistically, it was a week or less. The first real benefit was I did not feel the need to shop. I had this sudden burst of hope or responsibility to get both my shopping and hoarding under control. Since taking KB220Z in March, my personal relationships with my family have dramatically changed. Specifically, I feel that even though I have always been kind and compassionate, I noticed that now I feel more spiritually kind towards my family. I feel my quest for spirituality (faith) has always been a struggle for me and often confused, but ironically in the month of March, I felt as though I was found, or that I found myself opening up in a raw way to GOD. I selflessly opened up. I cried for days when that happened to me. In terms of my relationship with my mother, I am so much more patient, and have not acted passionately toward her when she has maybe said something hurtful or intentionally did something to hurt my feelings. My coping skills seemed to allow me to let things slide off my back and that is a first for me. Happily I report that I am softer towards her and can do kind and loving things for her because I am thinking about her feelings now. In the pre-KB220Z period, there was so much hate and resentment. I am learning how to like her/love her. In general I feel that KB220Z and my doctor (TM) are responsible for these beautiful changes in my life.""

Discussion {#S6}
==========

Previously our laboratory provided a neuromechanism for the pathogenesis of alcohol and non-alcohol-induced depression in animals and possibly humans ([@B12]). Since we found an effect of the KB220Z on the subject's mood (bipolar depression), it is incumbent upon us to provide a brief discussion of this notable finding. In fact, Archer et al. ([@B1]) and our group discussed the role of epigenetics in mood disorders concluding that mood disorders manifest in in many forms, varying from anxiety to severe major clinical depression. The disorders are the complex interactive operations of environmental and genetic factors expressed in individuals through manifestations governed by the effects of genes on phenotypes like comorbidities, symptom frequency, duration, and severity.

The notion of endophenotypes, which contain markers for several underlying disorders, may help to identify and detect genetic risks for disease states and assist the unraveling of the extreme complexity of disease states. Moreover, Blum, Febo, et al. ([@B16]) discussing SUD pointed out that relapse rate is due, in part, to untreated post-withdrawal and neurotoxicity. This impairment compromises resting state functional connectivity, by changing neurotransmitter signaling. The unwanted sequelae of these impairments include depression, lack of satisfaction and impulsivity, sleep disturbances, and sensation seeking. Neuroimaging studies reveal that neurobiological recovery can take years. SUD has a biological bidirectional (bio-directional) effect, like a "double edge sword," on the reward circuitry of the brain. Acute psychoactive drug intake increases dopaminergic activity, while, chronic intake the opposite, hypodopaminergia occurs following with misuse ([@B16]). Moreover, untreated hypodopaminergia is a key to relapse and may require not only 12 steps and fellowship but also epigenetic repair involving manipulation of impaired brain neurochemistry using pro-dopamine regulation directed at concomitant depressive states.

The attenuation of bipolar depression in this case study using KB220Z is in agreement with a number of other studies showing significant attenuation of depressive states following administration of this putative pro-dopamine regulator ([@B10]; [@B18]; [@B29]; [@B49]).

This patient provided a clinical history, consistent with the diagnosis of ADHD, inattentive type. The results of her Connors' Continuous Performance Test supported the ADHD diagnosis. She admitted to having many vocal and motor tics and reported that vocal tics occur in her mother as well. She reported having been diagnosed with "bipolar disorder" as an adolescent. The patient's addictions to opiates, caffeine, her prior history of marijuana addiction, and her addictions to shopping as well as to hoarding; all appear to be manifestations of RDS ([@B14]). Her reported history of lucid dreams has been reported in other patients, exhibiting RDS signs, symptoms, and diagnoses. The amelioration of these lucid dreams by KB200Z has been previously described. Finally, the complete termination of lucid dreams, even after the long-term cessation of KB200Z has also been documented, with the explanation advanced that these nutraceutical-induced neuroplasticity changes affected the reward system of the brain ([@B51]).

The KB220Z compound was an addition to C.J.'s usual medications, including mixed amphetamine salts. The dextroamphetamine/amphetamine mixture is a compound combining four amphetamine isomers. The drug blocks the reuptake and increases the release of catecholamines, specifically norepinephrine and DA ([@B66]). However, long-term use of amphetamines leads to tolerance, which may be due to depletion of DA ([@B61]). Therefore, adding DA precursors and stabilizing the DA system, via the adjunct therapy of KB220Z, may not only reverse this tolerance but may also augment the stimulants by reversing DA depletion ([@B101]). Furthermore, regarding RDS, creating DA homeostasis and stabilization can only be done by influencing multiple neurotransmitter pathways that converge on the DA brain reward cascade via a compound like KB220Z ([@B19]).

What is most striking in this patient's report is not only the cessation of her various addictive behaviors but also the activation of her psychological ego, resulting in a change from "passive victimhood" to her becoming an active agent, in control of her life, and her identity. She had changed from being a bored, hopeless, self-pitying victim to an activated agent, who had taken charge of her life. Many studies have evaluated the effect of this pro-dopaminergic regulator on psychological functions. In addition to its demonstrated anti-addiction effects, KB220Z or pro-dopamine regulation constitutes a potentially new and exciting area of brain--mind research.

Regarding both hoarding and shopping issues, the elimination of these unwanted behaviors in the patient is at the core of the mechanism of action of KB220Z. Previous work adequately showed not only selective DA activation across the brain reward circuitry ([@B37]), but also evidence for DA homeostasis in protracted heroin dependence ([@B17]; [@B23]).

Limitations {#S7}
===========

Currently, we do not know the actual level of "dopamine homeostasis" in the brain of this patient and although this question requires, additional, in-depth research in a much larger study her case provides an intriguing and provocative rationale for the further study.

A case study is descriptive research and, unlike true experimental placebo-control design, may help to generate experimental hypotheses rather than showing direct causality. The behavioral changes observed in this case study are consistent with a larger body of work, specifically, that of RDS and the use of the compound KB220Z. Based on this intervention, it is appropriate to extrapolate that the compound may have indeed influenced these profound behavioral changes. Finally, the mechanisms of action of KB220Z are well understood within the framework of the literature reviewed herein.

Conclusions {#S8}
===========

Based on this case study, the authors have demonstrated the elimination of many RDS-related behaviors, including lucid dreams, uncontrollable hoarding and shopping along with what appears to be enhanced motivation and activation of her psychological ego. Surprisingly, the latter reported change from "passive victimhood" to becoming an active agent, in control of her life and her identity is most intriguing.

The hypothesis that these benefits are the result of pro-dopamine regulation through KB220Z ([@B23]), potentially leading to a needed balance of DA across the brain reward system, requires testing in further larger placebo-controlled studies.
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